Business Wire

ADVA

8.6.2022 09:02:06 CEST | Business Wire | Press release

Share
Partner Communications utilizes ADVA synchronization solution for 5G timing

ADVA (FSE: ADV) today announced that Partner Communications has deployed its Oscilloquartz timing technology to support 5G rollout throughout Israel. The solution provides the level of accuracy and availability needed for next-generation mobile services and time-sensitive low-latency applications. Featuring ADVA’s Oscilloquartz core grandmaster devices, enhanced primary reference time clock (ePRTC) technology and multi-band GNSS receivers, the new timing infrastructure is ultra-resilient and prepared to withstand the rising threat of jamming and spoofing attacks. ADVA’s partner RDT Equipment & Systems also played a significant role in the deployment, carrying out installation, configuration and troubleshooting. Together with ADVA, it will provide Partner Communication with ongoing maintenance and support.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607006044/en/

“Upgrading a major nationwide mobile network like ours required the most advanced timing technology and the support of an expert team. That’s why we selected ADVA’s Oscilloquartz synchronization solution built on a core PTP grandmaster clock with full hardware redundancy and a scalable modular design. It offers many fan-out options, including PTP over multiple 10Gbit/s interfaces, and its advanced GNSS technologies ensure highest availability even under challenging conditions,” said Yigal Giladi, VP of engineering at Partner Communications. “With our new timing infrastructure, we can deliver the best possible mobile 5G experience to our customers. Now when GNSS is compromised or otherwise unavailable, ADVA’s ePRTC solution means we can still deliver phenomenally accurate timing across our network even during very long GNSS outages.”

Partner Communications’ new timing infrastructure features the OSA 5440 , a fully redundant, scalable, and modular multi-technology grandmaster for core deployment. Operating with the OSA 3230B ePRC cesium clock and OSA clock combiner, it provides an ePRTC system, providing high levels of time stability compliant with the ITU-T G.8272.1 standard. Onboard multi-band, multi-constellation receivers compensate for atmospheric disturbances to filter out timing errors. What’s more, centralized AI-powered GNSS assurance software identifies and protects against vulnerabilities of satellite-based timing. The solution also includes the OSA 5410 Series for continuous probing and assurance, enabling Partner Communications’ team to anticipate any issues and minimize disruption to service. The technology is remotely controlled by ADVA’s Ensemble Controller with Sync Director. This provides a powerful management platform, giving Partner Communications full visibility of its synchronization infrastructure and assuring accurate timing.

“Partner Communications has taken a major leap forward in terms of the accuracy and reliability of its synchronization network. Their team was determined to make their timing infrastructure the most precise and robust it could be, and so our engineers have worked tirelessly on design, testing and installation to ensure an end-to-end solution that delivers for Partner Communications’ customers now and for many years to come,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “This timing solution delivers a unique set of features to mitigate GNSS vulnerabilities, such as multi-band, multi-constellation receivers and AI-powered analytics. In a world of increasing jamming and spoofing attacks, this will prove invaluable for mobile users across Israel.”

About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye